-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Thermo Fisher Scientific Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$32.22 B | $39.21 B | $44.92 B | $42.86 B | $42.88 B |
| Cost of Revenue |
|
$15.71 B | $18.98 B | $25.42 B | $25.74 B | $24.77 B |
| Gross Profit |
|
$16.51 B | $20.23 B | $19.50 B | $17.11 B | $18.11 B |
| Research & Development |
|
$1.18 B | $1.41 B | $1.47 B | $1.34 B | $1.39 B |
| Selling,General & Administrative |
|
$5.76 B | $6.84 B | $7.13 B | $8.45 B | $8.60 B |
| Operating Expense |
|
$8.61 B | $10.01 B | $10.99 B | $10.25 B | $10.72 B |
| Operating Income |
|
$7.79 B | $10.03 B | $8.39 B | $6.86 B | $7.34 B |
| Net Income |
|
$6.38 B | $7.73 B | $6.95 B | $6.00 B | $6.34 B |
Thermo Fisher Scientific Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$10.33 B | $4.48 B | $8.52 B | $8.08 B | $5.57 B |
| Inventories |
|
$4.03 B | $5.05 B | $5.63 B | $5.09 B | $4.98 B |
| Total Current Assets |
|
$21.96 B | $20.11 B | $25.23 B | $24.59 B | $22.14 B |
| Property,Plant and Equipment |
|
$6.69 B | $9.86 B | $10.87 B | $9.45 B | $9.31 B |
| Goodwill |
|
$26.04 B | $41.92 B | $41.20 B | $44.02 B | $45.85 B |
| Total Assets |
|
$69.05 B | $95.12 B | $97.15 B | $98.73 B | $97.32 B |
| Total Liabilities |
|
$34.54 B | $54.15 B | $53.01 B | $51.88 B | $47.65 B |
| Retained Earnings |
|
$28.12 B | $35.43 B | $41.91 B | $47.36 B | $53.10 B |
| Total Shareholder Equity |
|
$34.51 B | $40.79 B | $43.98 B | $46.74 B | $49.55 B |
| Common Stock |
|
$437.00 M | $439.00 M | $441.00 M | $442.00 M | $444.00 M |
Thermo Fisher Scientific Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$2.33 B | $2.59 B | $3.38 B | $3.41 B | $3.11 B |
| Dividends Payout |
|
-$337.00 M | -$395.00 M | -$455.00 M | -$523.00 M | -$583.00 M |
| Capital Expenditures (Capex) |
|
-$1.47 B | -$2.52 B | -$2.24 B | -$1.48 B | -$1.40 B |
| Free Cash Flow (FCF) |
|
$6.82 B | $7.02 B | $6.91 B | $6.93 B | $7.27 B |
Thermo Fisher Scientific Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$16.51 B | $20.23 B | $19.50 B | $17.11 B | $18.11 B |
| Gross Profit Margin (%) |
|
51.23% | 51.60% | 43.42% | 39.93% | 42.23% |
| Operating Income |
|
$7.79 B | $10.03 B | $8.39 B | $6.86 B | $7.34 B |
| Operating Income Margin (%) |
|
24.19% | 25.57% | 18.69% | 16.00% | 17.11% |
| Net Income |
|
$6.38 B | $7.73 B | $6.95 B | $6.00 B | $6.34 B |
| Net Income Margin (%) |
|
19.79% | 19.70% | 15.47% | 13.99% | 14.77% |
| EBITDA |
|
$10.19 B | $12.96 B | $11.94 B | $11.08 B | $11.54 B |
| EBITDA Margin (%) |
|
31.63% | 33.06% | 26.59% | 25.85% | 26.90% |
Thermo Fisher Scientific Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
18.47% | 18.94% | 15.80% | 12.83% | 12.78% |
| Return on Assets (ROA) |
|
9.23% | 8.12% | 7.15% | 6.07% | 6.51% |
| Debt to Equity |
|
62.99% | 85.48% | 78.42% | 74.71% | 63.12% |
| Debt to total asset |
|
31.48% | 36.66% | 35.50% | 35.37% | 32.14% |
| Enterprise value to revenue |
|
6.08 | 7.48 | 5.38 | 5.41 | 5.27 |
| Enterprise value to EBITDA |
|
19.22 | 22.62 | 20.25 | 20.92 | 19.59 |
| Enterprise value |
|
$195.86 B | $293.29 B | $241.83 B | $231.72 B | $225.99 B |
| Cash to Debt |
|
38.14% | 27.37% | 26.54% | 24.07% | 27.71% |
| Tax Rate (%) |
|
11.76% | 12.54% | 8.97% | 4.51% | 9.34% |
| Payout Ratio |
|
5.29% | 5.11% | 6.55% | 8.72% | 9.20% |
